Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
研究单位：[1]BeiGene[2]The First Affiliated Hospital of Wannan Medical College,Wuhu,Anhui,China,241001[3]Xuanwu Hospital Capital Medical University,Beijing,Beijing,China,100053[4]Beijing Cancer Hospital,Beijing,Beijing,China,100142[5]Fujian Medical University Union Hospital,Fuzhou,Fujian,China,350001[6]The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China,510120[7]The Tumor Hospital Affiliated to Guangxi Medical University,Nanning,Guangxi,China,530021[8]Affiliated Hospital of Hebei University,Baoding,Hebei,China,071000[9]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150000[10]Anyang Cancer Hospital,Anyang,Henan,China,455001[11]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052[12]Hubei Cancer Hospital,Wuhan,Hubei,China,400037[13]Hunan Cancer Hospital,Changsha,Hunan,China,410013[14]The First Affiliated Hospital of Nanchang University Branch Xianghu,Nanchang,Jiangxi,China,332000[15]Liaoning Cancer Hospital and Institute,Shenyang,Liaoning,China,110042[16]Rui Jin Hospital Shanghai Jiao Tong University School of Medicine,Shanghai,Shanghai,China,200025[17]Shanghai Pulmonary Hospital,Shanghai,Shanghai,China,200433[18]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310003[19]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310022[20]Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital),Ningbo,Zhejiang,China,315000
研究目的：
This is a randomized, open-label, multicenter, Phase 2, umbrella study to evaluate the preliminary efficacy, safety, and pharmacodynamics of tislelizumab as monotherapy and in combination with investigational agents as neoadjuvant treatment in Chinese participants with resectable Stage II to IIIA non-small cell lung cancer (NSCLC). The study is designed with the flexibility of adding treatment arms as new treatments become available or discontinuing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, and of modifying the participant population.
